Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 901–1,000 of 1,139
Dyslipidemia in cardio-reno-metabolic syndrome
Karásek, D. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.071
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Self-citationThe importance of science communication surrounding weight-loss drugs
Yeo, G. S. H. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00320-1
Recent Progression of Incretin-Based Obesity Treatment
Choi, D. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.2.78
Салухов, В. В., Arutyunov, G. P., Vasilyeva, I. A., Cherkashin, D. V., Prochik, Y. E., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-136
Hypogonadism and Metabolic Disorders
Cignarelli, A., Genchi, V. A., & Jayasena, C. N. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_50-1 · Cited by 1
Ferreira, M. H. L., Câmara, L. C., Mattoso, S. O., Pereira, S. I. D. S., de Aguiar, D. R., & Khan, Z. U. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02580-9
“Two randomized controlled trials [ 19 , 31] with follow-up durations ranging from 48 to 68 weeks evaluated the effect of retatrutide on body weight in adults with overweight or obesity ( n = 428).”
InfluentialChalhoub, X., & Ng, Z. Y. (2026) · Aesthetic Surgery Journal · doi:10.1093/asj/sjag108 · Cited by 1
Clavet, M. J., & Trivieri, I. (2026) · The Journal of Physiology · doi:10.1113/jp291532
Current status of novel weight loss interventions
Tariq, N., Jacobucci, R. P., & Ali, A. B. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241241403
Rajcsanyi, L. S., Schmidt, J., Düerkop, S., Grote, L., Peters, T., Körner, A., Fischer‐Posovszky, P., & Hinney, A. (2024) · Diabetes aktuell · doi:10.1055/a-2325-4522
Sztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
Lu, D., Li, N., Yuan, Z., & Gao, Y. (2026) · Clinical Obesity · doi:10.1111/cob.70112
Hat die inkretinbasierte Hypertoniebehandlung eine Zukunft?
Zidek, W. (2026) · CardioVasc · doi:10.1007/s15027-025-3944-5
Santulli, G. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00321-4
“Triple agonists extending co-agonism to glucagon receptors, most notably retatrutide (GLP-1R/GIPR/GCGR), are in late clinical development [4, 8, 9, 16, 17, 19].”
Roser, U. (2026) · German Journal of Sports Medicine · doi:10.5960/dzsm.2026.667
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Obesity and hypertension new insights in management
Catalfamo, V. J., Koos, A., Tutor, A. W., & Lavie, C. J. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001261
La medicina cardiometabolica nell’obesità
(2024) · il Diabete · doi:10.30682/ildia2304d
“Retatrutide, un agonista settimanale dei recettori GIP, GLP-1 e glucagone, che è il primo triplo agonista studiato in ampi RCT (Randomized Controlled Trials) per il trattamento dell’obesità (77) e T2D (78), ha portato a significativi mi-glioramenti in entrambi.”
BackgroundMahajan, N., Kaur, N., Sandhu, S. P. S., Patel, V., Boparai, H. K., Singh, K., & Singh, F. R. (2026) · Cureus · doi:10.7759/cureus.115501
A proteomic atlas of obesity and weight loss
Suriani, N. D., & Watt, M. J. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01601-0
Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments
Zhou, R., Yin, G., Zhu, Y., & Sun, Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166473
“Reta-trutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, has demonstrated substantial weight-lowering potential (up to 24% weight reduction at 48 weeks) in phase 2 obesity trials [33].”
Varas, N., Grabowski, R., Jarosinski, M. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.20.594997
“Although not appropriate for management of T1D, these and related peptides are also under regulatory review for the treatment of obesity in the absence of diabetes (40, 62-64).”
BackgroundADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Treatment Decision-making and Weight Loss Expectations for Current Obesity Treatment
Paknikar, S. S., & Shah, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00691-x
“In a phase two clinical trial, the triple agonist therapy (GlP-1, GIP, Glucagon receptor agonist therapy) retatrutide demonstrated weight loss of > 25% in nearly half of the cohort [47].”
He, K., Wei, Y., Zhao, H., Zhang, L., Wu, F., Liu, R., Zhang, Y., Wang, Y., Chen, H., ZENG, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71218 · Cited by 1
La poesía corsa más allá de las lenguas
Durazzo, F.-M. (2007) · Zurgai: Euskal herriko olerkiaren aldizkaria : Poetas por su pueblo
Goldenberg, R., Ibrahim, C., & Trinacty, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71331
Wei, T. (2012)
Iwona, K., Gawalska, A., Kasprzycka, P., Stępniewski, M., Rózga, P., Pałka, A., Shubin, A., Bukato, K., Galazka, M., Burchard, E., et al. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01086a
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752 · Cited by 2
“The triple hormone receptor agonist retatrutide is an agonist of the GIP, GLP-1, and glucagon receptors and resulted in substantial reductions in body weight in adults with obesity in a phase 2 study [83].”
Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
Zhang, J. K., Gao, G., He, M., & Sun, T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178921
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
Actividad Física, Ejercicio y Salud: Retos Actuales y Desafíos Futuros
Jiménez‐Pavón, D. (2024) · Revista Andaluza de Medicina del Deporte · doi:10.33155/ramd.v17i1-2.1172 · Cited by 1
Farmaci innovativi per il trattamento dell’obesità
Masi, D., Tuccinardi, D., & Watanabe, M. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01535-3 · Cited by 1
Popa, E., Popa, A. E., Poroch, V., Schreiner, T. G., Slănină, A. M., Poroch, M., Hatneanu, A. M., Ungureanu, M. I., Petroaie, A. D., Bacușcă, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198738
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
“…在此基础上 , GLP-1R/GIPR/GCGR 三重激动剂 ( 如瑞 他鲁肽 ) 的研发进一步推动了疗效边界。胰高血糖素受体 ( Glucagon Receptor , GCGR ) 激动具备促进肝脏消耗 、 提高 基础代谢率的能力 , 促进糖异生的风险又可以被 GLP-1R 的激动规避 [ 15-17 ] 功能障碍与慢性炎症等多通路协同损伤 [ 24 ] 。在早期开 发中 , 大量靶向单一机制的药物 ( 如 FXR 激动剂 、 乙酰辅 酶 A 羧化酶 ACC 抑制剂 、 趋化因子受体 CCR2/5 拮抗剂等 ) 因疗效有限或安全性问题在临床遭遇瓶颈 , 暴露出单靶 策略难以全面逆转…”
MASH and the race for liver antifibrotics
Wills, Q. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2025.1704078 · Cited by 1
“Multi-agonist molecules being trialled include the glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide (55), the amylin receptor agonist amycretin (56), the glucagon receptor agonist survodutide (57), and the glucagon + GIP receptor agonist retatrutide (58, 59).”
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Sun, R., Ronxhi, J., Yang, X., Qian, M. G., & Zhang, X. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116582
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
“Retatrutide (a triple agonist) demonstrated clinically relevant improvements in glycemic control and weight in type 2 diabetes and obesity [91,92].”
Cline, L., & Wilson, E. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.002 · Cited by 1
Rasmussen, R. S., Nielsen, S. W., Alstrup, L., Larsson, T. S. W., Hansen, J. K., Pedersen, R. P., Vestergaard, M. B., Haddock, B., Johannesen, H. H., Larsson, H. B. W., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06788-1 · Cited by 1
Chepurny, O. G., Liles, A. N., Cham, N., Matsoukas, M., Liapakis, G., Meng, Q., Cooney, R. N., Doyle, R. P., & Holz, G. G. (2025) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2025.114745
Hormone therapy boosts tirzepatide weight loss in menopause
Vettor, R., & Watanabe, M. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(25)00210-9
Lange, M. G., & Kalidindi, S. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07704-z
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
King, J. A., Aithal, G. P., Herring, L. Y., Willis, S. A., Papamargaritis, D., Hulley, K., & Davies, M. J. (2024) · NIHR Open Research · doi:10.3310/nihropenres.13784.1
“The weight loss induced by tirzepatide 15 mg is greater than semaglutide 2.4 mg 7 .”
InfluentialTraitement pharmacologique des obésités complexes d’origine génétique
Faccioli, N., Dubern, B., Clément, K., & Poitou, C. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)48025-6
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
(Medikamentöse) Blutzuckereinstellung
Mathew, A., & Führer‐Sakel, D. (2025) · DGNeurologie · doi:10.1007/s42451-025-00731-1
EFFECTIVENESS OF SEMAGLUTIDE IN OBESITY TREATMENT AND THE ROLE OF LIFESTYLE INTERVENTIONS
Bracichowicz, F., Winogrodzki, I., Kowalczyk, P., Paszkiewicz, H., Nowak, K., Gęsińska, A., Stryczek-Schlusche, A., Trzciński, B., Gugała, O., & Furczyńska, A. M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3931
Midlife weight gain: challenges and solutions
Hung, S., & Adams, K. E. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001093 · Cited by 1
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
Effects of Retatrutide on Learning and Memory in Streptozotocin-Induced Male Diabetic RatsPreprint
Keskin, U., Altın, E., Melkan Kagan, K. A. R. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.23.701347
Huang, Y., Yang, R., Wang, Y., Lu, X., Wei, L., Cheng, R., Cheng, J., Qiu, Y., Wang, S., Li, B., et al. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70035 · Cited by 1
FATEHI, S., Rocheleau, J. V., & Riddell, M. C. (2026) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.70384
“This synthetic peptide has been shown to effectively lower blood glucose levels and promote weight loss by targeting GLP-1, GIP, and glucagon receptors in clinical trials [ 124, 125 ].”
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Die Zukunft gehört den Polyagonisten
Glaser, A. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4573-7
Nasri, H., Chitsazi, M. R., Abbasi, F., Ashouri, A. H., Rouzbahani, H., Mirzaei, S. A., Golafshan, F., Noursina, A., & Safari, F. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00884-9
Ciaula, A. D., & Portincasa, P. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03448-9
Kenkishvili, A. S., Arutyunyan, M. E., Maksimov, М. L., & Yassin, S. B. (2026) · doi:10.33920/med-13-2602-03
Rea, F., Muraca, E., Morabito, G., Oltolini, A., Bongo, A., Perseghin, G., Corrao, G., & Ciardullo, S. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07911-8
“Even in an era when pharmacological therapies might achieve weight loss goals similar to those achieved with surgery [33], metabolic and bariatric surgery could still represent an intervention able to improve quality of life and favorably impact healthcare costs related to drug assumption.”
Management of type 2 diabetes after metabolic bariatric surgery
Tham, K. W., & Lee, P. C. (2023) · Mini-invasive Surgery · doi:10.20517/2574-1225.2023.80 · Cited by 1
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Hormonal Regulation of Protein Metabolism: Mechanisms and Clinical Implications
Boirie, Y., & Christelle, G. (2026) · Endocrinology · doi:10.1007/978-3-030-71067-5_5-1
Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies
Amoyel, M., Carette, C., Poghosyan, T., Beyec, J. L., & Gall, M. L. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag032
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“…3 trials support tirzepatide 15 mg as a high-efficacy option, achieving approximately 22.5% weight loss, while retatrutide has been reported to approach 24% weight reduction at 48 weeks in selected datasets, magnitudes that approach those observed with bariatric surgical interventions [47, 51].”
InfluentialZhang, S., Liu, S., Zhou, M., Wang, J., Zhang, Y., Zhong, H., & Ning, G. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06090-6
Xiao, Y., Chen, J., Guo, M., Liu, X., Xu, X.-M., Yan-qun, L., Jiang, Z., Xu, Y., & Deng, C. (2025) · Research Square · doi:10.21203/rs.3.rs-7103001/v1 · Cited by 1
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.013
RetractedSemaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“In a 48-week phase 2 obesity trial, participants achieved remarkable weight reductions of 22.8% and 24.2% with the 8 mg and 12 mg doses, respectively [36].”
InfluentialKolaczynski, J. W., & Surmacz, E. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101449
Lifestyle Factors Affecting Biological Processes and Health
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00009-0
Leitlinienkonforme Adipositastherapie: Medikamentöse Therapie und Langzeitperspektiven
Engeli, S. (2025) · CardioVasc · doi:10.1007/s15027-025-3784-3
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Abramov, V. V., & Maksimov, M. L. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2407-03
Self-Reported Side Effects Among Reddit Users Taking Nonapproved RetatrutidePreprint
Sehgal, N. K. R., Tronieri, J. S., Rader, B. M., Ungar, L., & Guntuku, S. C. (2026) · medRxiv · doi:10.64898/2026.05.28.26352819
NEW ERA IN DIABETES AND OBESITY TREATMENT - THE EFFECTS OF GLP-1R, GIPR AND GCGR TRIAGONISTS
Duliński, M., Gofron, K. K., Kaźmierkiewicz, K., Spychalska, W., Piotrowicz, E., Witowicz, F., Glińska, J., Krawczyk, A., Waldon, W., & Sumlet, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6156
Ruotolo, G., Harris, C., Lin, Y., Wilson, J. M., Pirro, V., Duffin, K. L., Thomas, M. K., Hartman, M. L., Neill, C. O., Coşkun, T., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71200 · Cited by 1
“The study designs, methods and primary results have been re-ported for the phase 2 trial in adults with obesity/overweight without T2D (NCT04881760) and the phase 2 trial in adults with T2D and obesity/overweight (NCT04867785) [15, 16].”
Self-citationSkowron, W., Skowron, M., Łapot, M., Hober, K., Krupnik, D., Bzdak, W., Szwemińska, P., Górak, J., & Neumann, W. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6241
Blocking Arteries to Block Obesity
Pirlet, C., & Bertrand, O. F. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03774-1
“The latter, retatrutide, may yield weight reduction of up to 22.1% total body weight after one year compared to placebo [1].”
Influential孟, 黎. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.52111
Kaczynski, M., Zureikat, R. M., Kaczynski, M. R., Sitarz, R., & Karakuła‐Juchnowicz, H. (2026) · Biomedicines · doi:10.3390/biomedicines14091957
“That absence is structural rather than incidental: the Phase 2 obesity trial reported no psychiatric outcomes [27], and TRANSCEND-T2D-1 excluded severe psychiatric disorder at entry [91].”
InfluentialIncretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Cutting Edge Developments in Diabetes
Clifton, P. M. (2023) · Diabetology · doi:10.3390/diabetology4030024
“Participants who received the two highest doses lost more than 24% of their body weight, whereas all participants lost at least 5% of their body weight [10].”
BackgroundDu, J., Yang, Z., & Chen, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1870484 · Cited by 1
“Although retatrutide has shown substantial weight-loss efficacy in adults with obesity, the relative contributions of reduced appetite, altered food reward, enhanced energy expenditure, and glucagon-related metabolic effects remain incompletely understood (109).”
Bruenderman, E. H., Eisa, M., Pearlman, M. Y., & Mundi, M. S. (2026) · Current Surgery Reports · doi:10.1007/s40137-026-00537-4
Coleman, S., Lynch, C., Worlikar, H., Kelly, E., Loveys, K., Simpkin, A. J., Walsh, J. C., Broadbent, E., Finucane, F. M., & Keeffe, D. O. (2024) · doi:10.2196/preprints.63503
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Corona, G., Sparano, C., Romeo, M., Sedigh, O., Bettocchi, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260045
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
“Adverse effects with retatrutide were dose related and predominantly gastrointestinal in nature [81].”
InfluentialEmerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care
Gnanathayalan, S. W., & Sumanatilleke, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_110_23
Maximizing Obesity Therapy: Strategic Use of Anti-obesity Pharmacotherapy
Bartfield, J. K., & Bonnecaze, A. K. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_70
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.